# Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

> **NCT01702428** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 5016 (actual)

## Conditions studied

- Rubella
- Measles
- Mumps

## Interventions

- **BIOLOGICAL:** Priorix
- **BIOLOGICAL:** M-M-R II
- **BIOLOGICAL:** Varivax
- **BIOLOGICAL:** Havrix
- **BIOLOGICAL:** Prevnar 13

## Key facts

- **NCT ID:** NCT01702428
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-09
- **Primary completion:** 2014-11-25
- **Final completion:** 2015-04-16
- **Target enrollment:** 5016 (ACTUAL)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702428, "Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01702428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*